Author: admin

Schneider Electric Announces Farrukh Shad As the New Head of Sustainability Business for APMEA Region

Schneider Electric, the leader in the digital transformation of energy management and automation announced the appointment of Farrukh Shad as Head of Sustainability Business for the Asia Pacific, India, Middle East and Africa (APMEA) region.

In his new role based in Hong Kong, Shad will spearhead Schneider Electric’s sustainability business division across one of the company’s most important growth regions. With over 25 years of experience across multiple sectors, Shad brings a wealth of knowledge that will be instrumental as he leads Schneider Electric’s climate mitigation efforts and helps large enterprises in APMEA reduce carbon emissions.

“We are pleased to welcome Farrukh Shad to lead our sustainability endeavors across APMEA,” said Steve Wilhite, Senior Vice President, Sustainability Business at Schneider Electric. “With his innovative thinking, passion for sustainability and impressive track record of driving strategic transformation, we are confident he will take our business to new heights and advance our mission of building a more sustainable future.”

Over the past decade at Schneider Electric, Shad has led business transformation initiatives and advocated for active energy management and sustainability. He will now focus on transitioning Schneider Electric’s clients from passive to active energy management and supporting their renewable energy and carbon neutrality goals, while leveraging technology to maximize sustainability impact.

Prior to joining Schneider Electric, Shad held leadership roles in sales, marketing, strategy and more at global companies including L’Oreal, British Petroleum and Philips.

With its integrated efficiency solutions for energy, automation and software, Schneider Electric is at the forefront of digital transformation for energy management. Shad’s appointment represents the company’s ongoing commitment to sustainability and purpose-driven business.

About Schneider Electric

Schneider’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On.

Our mission is to be your digital partner for Sustainability and Efficiency.

We drive digital transformation by integrating world-leading process and energy technologies, end-point to cloud connecting products, controls, software and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure and industries.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric Announces Farrukh Shad As the New Head of Sustainability Business for APMEA Region

Schneider Electric Appoints Joey Walters as VP of Human Resources in Canada

Schneider Electric, the leader in the digital transformation of energy management and automation, has appointed Joey Walters as Vice President, Human Resources in Canada. Joining the esteemed executive team, Joey brings a robust blend of HR expertise and a deep-rooted commitment to growing Schneider Electric’s values-driven company culture.

With over 20 years of experience in talent and human resources management, Joey will lead the development and implementation of human resources strategies in Canada. He will be responsible for overseeing talent acquisition, employee engagement, compensation and benefits, and talent development.

“I am beyond excited to join Schneider Electric,” says Joey Walters, VP, Human Resources for Schneider Electric Canada. “Their dedication to shaping a sustainable future through digital transformation resonates deeply with me. I’ve long admired Schneider Electric’s people-centric approach, and I’m eager to leverage my experience in the energy industry and HR to foster an environment where talent thrives and innovation flourishes.”

Previously serving as Vice President of HR at Carrier Enterprise Canada for over a decade, Joey’s extensive experience in human resources leadership strongly positions him to spearhead Schneider Electric’s HR initiatives. His previous experience also includes working with BroadGrain Commodities, Ingersoll Rand, and Ameresco Canada.

“We are delighted to welcome Joey to the Schneider Electric team,” says Emily Heitman, Country President for Schneider Electric Canada. “His proven track record in HR management, coupled with his passion for the industry and cultivating talent, perfectly aligns with our company’s values and strategic objectives. With Joey on board, I’m confident we will continue to elevate our commitment to sustainability and drive organizational excellence. We’re looking forward to him taking Schneider Electric’s people-first culture to new heights.”

Joey succeeds Claire Guichard, who has assumed the role of VP, HR Commercial & Segments, Strategy and Central Finance, Industrial Automation.

About Schneider Electric

Schneider’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On.

Our mission is to be your digital partner for Sustainability and Efficiency.

We drive digital transformation by integrating world-leading process and energy technologies, endpoint to cloud connecting products, controls, software and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure and industries.

We are the most local of global companies. We are advocates of open standards and partnership ecosystems that are passionate about our shared Meaningful Purpose, Inclusive and Empowered values.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric Appoints Joey Walters as VP of Human Resources in Canada

Antibody Drug Conjugates Market to Register Incremental Growth During the Forecast Period (2024-2034), Asserts DelveInsight | Bristol Myers Squibb, GSK, MBrace therapeutics, Oxford Biotherapeutics

The Antibody Drug Conjugates Market report offers an in-depth understanding of the Antibody Drug Conjugates, historical and forecasted epidemiology as well as the Antibody Drug Conjugates market trends in the 7MM.

DelveInsight’s “Antibody Drug Conjugates Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Antibody Drug Conjugates, historical and forecasted epidemiology as well as the Antibody Drug Conjugates market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Antibody Drug Conjugates market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Antibody Drug Conjugates Market Forecast

 

Some of the key facts of the Antibody Drug Conjugates Market Report: 

  • The Antibody Drug Conjugates market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In January 2024, RemeGen declared that RC88, an ADC targeting mesothelin, received Fast Track Designation (FTD) from the United States Food and Drug Administration (US FDA) for potential treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

  • In January 2024, Debiopharm revealed an extension of their exclusive licensing agreement with SunRock Biopharma, aimed at developing cutting-edge ADCs. SunRock Biopharma will leverage Debiopharm’s Multilink technology to develop an improved HER3-EGFR bispecific ADC.

  • Key Antibody Drug Conjugates Companies: Bristol Myers Squibb, GSK, MBrace therapeutics, Oxford Biotherapeutics, Pfizer/Seagen, Abbvie/ImmunoGen, Adcendo, AdcentrX Therapeutics, Alentis Therapeutics, Araris Biotech, AstraZeneca/Daiichi Sankyo, BioNTech/DualityBio, Roche, Takeda Pharmaceuticals, and others

  • The Antibody Drug Conjugates market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Antibody Drug Conjugates pipeline products will significantly revolutionize the Antibody Drug Conjugates market dynamics.

 

Antibody Drug Conjugates Overview

Antibody Drug Conjugates (ADCs) represent a cutting-edge class of cancer therapeutics that harness the specificity of monoclonal antibodies to deliver potent cytotoxic drugs directly to cancer cells. This innovative treatment approach has gained significant attention in recent years due to its potential to enhance the efficacy of cancer treatments while minimizing systemic toxicity. The global burden of cancer is ever-growing, with the World Health Organization (WHO) estimating that cancer is the second leading cause of death globally. ADCs are emerging as a promising tool in the fight against various types of cancer, contributing to the evolving landscape of oncology.

 

Get a Free sample for the Antibody Drug Conjugates Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/antibody-drug-conjugate-market

 

Signs, Symptoms, and Risk Factors of Antibody Drug Conjugates

Unlike traditional chemotherapy, ADCs aim to minimize the impact on healthy cells by selectively targeting cancer cells. Signs and symptoms associated with ADCs may vary depending on the specific cancer type being treated. Common adverse effects include fatigue, nausea, and potential immune system reactions. Risk factors for adverse events may include the patient’s overall health status, pre-existing medical conditions, and the specific combination of antibodies and cytotoxic drugs used in the ADC.

 

Diagnosis of Antibody Drug Conjugates

Diagnosing the effectiveness and safety of ADCs involves comprehensive monitoring of the patient’s response to treatment. This includes regular assessments of tumor size, imaging studies, and laboratory tests to evaluate potential side effects. As with any cancer treatment, close collaboration between healthcare providers and patients is crucial to promptly address any emerging concerns and optimize the therapeutic outcome.

 

Antibody Drug Conjugates Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Antibody Drug Conjugates Epidemiology Segmentation:

The Antibody Drug Conjugates market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Antibody Drug Conjugates

  • Prevalent Cases of Antibody Drug Conjugates by severity

  • Gender-specific Prevalence of Antibody Drug Conjugates

  • Diagnosed Cases of Episodic and Chronic Antibody Drug Conjugates

 

Download the report to understand which factors are driving Antibody Drug Conjugates epidemiology trends @ Antibody Drug Conjugates Epidemiology Forecast

 

Evolving Treatment Outlook for Antibody Drug Conjugates

The evolving treatment outlook for ADCs is characterized by ongoing research and development aimed at refining their efficacy and safety profiles. Major treatment options involve optimizing the design of monoclonal antibodies, enhancing the potency of cytotoxic payloads, and improving the linker technology that connects the antibody and the drug. This continuous refinement seeks to broaden the spectrum of cancers that can be effectively treated with ADCs and improve the overall therapeutic index.

 

Antibody Drug Conjugates Market Strengths

  • Expanded therapeutic window, due to the increased tolerability and safety provided by linker chemistry, higher doses of toxin carrying ADCs can be administered to patients leading to increased therapeutic efficacy while minimizing the adverse effects. 

  • The pharmacodynamics properties of ADCs make them uniquely suited for activity in treatment-refractory cancers, which is reflected in the current approved clinical indications for ADCs in oncology.

 

Antibody Drug Conjugates Market Opportunities

  • Important and potentially practice-changing innovations in ADC design, biomarker development and combination therapies are ongoing in preclinical and clinical studies. 

  • Antibody drug conjugates can overcome several traditional problems, including the narrow therapeutic window, low selectivity, and rapid plasma clearance of chemotherapy, as well as the unsatisfactory antitumor efficacy of targeted therapy. 

 

Scope of the Antibody Drug Conjugates Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Antibody Drug Conjugates Companies: Bristol Myers Squibb, GSK, MBrace therapeutics, Oxford Biotherapeutics, Pfizer/Seagen, Abbvie/ImmunoGen, Adcendo, AdcentrX Therapeutics, Alentis Therapeutics, Araris Biotech, AstraZeneca/Daiichi Sankyo, BioNTech/DualityBio, Roche, Takeda Pharmaceuticals, and others

  • Antibody Drug Conjugates Therapeutic Assessment: Antibody Drug Conjugates current marketed and Antibody Drug Conjugates emerging therapies

  • Antibody Drug Conjugates Market Dynamics: Antibody Drug Conjugates market drivers and Antibody Drug Conjugates market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Antibody Drug Conjugates Unmet Needs, KOL’s views, Analyst’s views, Antibody Drug Conjugates Market Access and Reimbursement 

 

To know more about Antibody Drug Conjugates companies working in the treatment market, visit @ Antibody Drug Conjugates Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Antibody Drug Conjugates

4. Key Events

5. Market Forecast Methodology

6. ADCs Market Overview at a Glance in the 7MM in (2023 and 2024)

7. ADCs: Background and Overview

8. Antibody Drug Conjugates Target Population

9. Antibody Drug Conjugates Marketed Therapies

10. Antibody Drug Conjugates Emerging Therapies

11. Antibody Drug Conjugates: Seven Major Market Analysis

12. KOL Views

13. Antibody Drug Conjugates Unmet Needs

14. SWOT Analysis

15. Market Access and Reimbursement

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Antibody Drug Conjugates Market to Register Incremental Growth During the Forecast Period (2024-2034), Asserts DelveInsight | Bristol Myers Squibb, GSK, MBrace therapeutics, Oxford Biotherapeutics

Advanced Renal Cell Carcinoma Market Report 2034: Epidemiology Data, Therapies, Latest Drug Approvals | DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis, AVEO

The Advanced Renal Cell Carcinoma Market report offers an in-depth understanding of the Antibody Drug Conjugates, historical and forecasted epidemiology as well as the Antibody Drug Conjugates market trends in the 7MM.

DelveInsight’s “Advanced Renal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Antibody Drug Conjugates, historical and forecasted epidemiology as well as the Antibody Drug Conjugates market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Advanced Renal Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Advanced Renal Cell Carcinoma Market Forecast

 

Some of the key facts of the Advanced Renal Cell Carcinoma Market Report: 

  • The Advanced Renal Cell Carcinoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In December 2023, Exelixis and Arcus Biosciences have announced a collaborative effort for the STELLAR-009 clinical trial, a Phase Ib/II study assessing zanzalintinib, Exelixis’ advanced tyrosine kinase inhibitor (TKI), in conjunction with AB521, a transcription factor HIF-2⍺ inhibitor, in patients with advanced solid tumors, including ccRCC. Exelixis is leading the sponsorship of the STELLAR-009 trial, while Arcus is contributing to the funding and providing AB521 for the study. Patient recruitment for the STELLAR-009 trial is anticipated to commence by the conclusion of 2023.

  • In July 2023, The Chinese National Medical Products Administration (NMPA) has assessed a supplementary new drug application (sNDA) seeking approval for the utilization of toripalimab (Tuoyi) in conjunction with axitinib (Inlyta) as a primary treatment option for patients afflicted with unresectable or metastatic renal cell carcinoma (RCC). This submission is supported by data obtained from an interim analysis of the phase 3 RENOTORCH trial (NCT04394975), revealing that the combined treatment regimen led to improved progression-free survival (PFS) in comparison to the use of the single-agent sunitinib (Sutent).

  • In April 2023, At the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, Allogene Therapeutics presented interim results from its Phase 1 TRAVERSE trial, which focuses on ALLO-316, the company’s primary AlloCAR T investigational product developed for treating solid tumors. The data exhibited encouraging early antitumor effects and a favorable safety profile of the novel anti-CD70 allogeneic CAR T-cell therapy, ALLO-316, particularly when administered at lower doses. These findings suggest that this treatment regimen holds promise as a potential new therapeutic approach for heavily treated patients with advanced clear cell renal cell carcinoma (ccRCC) expressing CD70.

  • In April 2023, Shanghai Junshi Biosciences Co., Ltd. has reported the completion of the planned interim analysis for the RENOTORCH trial (NCT04394975). This phase 3 clinical trial is a multicenter, randomized, open-label study investigating the efficacy of combining toripalimab with axitinib as a first-line therapy for patients with intermediate to high-risk, unresectable, or metastatic renal cell carcinoma (RCC). The Independent Data Monitoring Committee (IDMC) has verified that the primary endpoint of progression-free survival (PFS), assessed through an independent radiographic review, has met the predetermined efficacy criteria.

  • In January 2023, Teon Therapeutics announced a partnership with Merck, with a particular emphasis on the combination arm of Teon’s current clinical trial. The trial comprises two arms: an open-label, dose escalation, and expansion phase. Its objective is to evaluate TT-816, Teon’s oral immune response modifier, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for patients dealing with advanced solid tumors.

  • The Canadian Medical Association Journal (CMAJ) of 2024 states that the occurrence of RCC rises as individuals get older, typically diagnosed around the age of 75 globally. Additionally, males are twice as likely as females to develop this condition.

  • As per the Canadian Medical Association Journal (CMAJ) in 2024, the general survival expectancy for metastatic RCC is roughly 4 years. Nevertheless, this duration may fluctuate based on variables like the patient’s age, performance level, and any accompanying health conditions.

  • Key Advanced Renal Cell Carcinoma Companies: Dana-Farber Cancer Institute, Huabo Biopharm Co., Ltd., Beijing Scitech-Mq Pharmaceuticals, Oxford BioMedica, Hutchison Medipharma Limited, Takeda, Amgen, Novartis, AVEO Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, Pfizer, Calithera Biosciences, Inc, AbbVie, Bristol-Myers Squibb, Abbott, SCRI Development Innovations, LLC, Astellas Pharma Inc, and others

  • Key Advanced Renal Cell Carcinoma Therapies: Bevacizumab, HB0025, ST-1898 tablets, Trovax, fruquintinib+sintilimab, Cabozantinib, AMG 102, Pazopanib, tivozanib (AV-951), Belzutifan, Temsirolimus (CCI-779), CB-839, ABT-869, Nivolumab, ABT-510/Thrombospondin-1 mimetic, bevacizumab, CP-461, and others

  • The Advanced Renal Cell Carcinoma epidemiology based on gender analyzed that Males are slightly more affected in the case of Advanced Renal Cell Carcinoma

  • The Advanced Renal Cell Carcinoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Advanced Renal Cell Carcinoma pipeline products will significantly revolutionize the Advanced Renal Cell Carcinoma market dynamics.

 

Advanced Renal Cell Carcinoma Overview

Advanced Renal Cell Carcinoma (RCC), also known as advanced kidney cancer, refers to cancer that has spread beyond the kidney and nearby lymph nodes to other parts of the body. Renal cell carcinoma originates in the cells of the kidney’s tubules, which are tiny tubes that filter blood and remove waste products to form urine.

 

Get a Free sample for the Advanced Renal Cell Carcinoma Market Report:

https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market

 

Advanced Renal Cell Carcinoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Advanced Renal Cell Carcinoma Epidemiology Segmentation:

The Advanced Renal Cell Carcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Advanced Renal Cell Carcinoma

  • Prevalent Cases of Advanced Renal Cell Carcinoma by severity

  • Gender-specific Prevalence of Advanced Renal Cell Carcinoma

  • Diagnosed Cases of Episodic and Chronic Advanced Renal Cell Carcinoma

 

Download the report to understand which factors are driving Advanced Renal Cell Carcinoma epidemiology trends @ Advanced Renal Cell Carcinoma Epidemiology Forecast

 

Advanced Renal Cell Carcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Advanced Renal Cell Carcinoma market or expected to get launched during the study period. The analysis covers Advanced Renal Cell Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Advanced Renal Cell Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Advanced Renal Cell Carcinoma Therapies and Key Companies

  • Bevacizumab: Dana-Farber Cancer Institute

  • HB0025: Huabo Biopharm Co., Ltd.

  • ST-1898 tablets: Beijing Scitech-Mq Pharmaceuticals

  • Trovax: Oxford BioMedica

  • fruquintinib+sintilimab: Hutchison Medipharma Limited

  • Cabozantinib: Takeda

  • AMG 102: Amgen

  • Pazopanib: Novartis

  • tivozanib (AV-951): AVEO Pharmaceuticals, Inc.

  • Belzutifan: Merck Sharp & Dohme LLC

  • Temsirolimus (CCI-779): Pfizer

  • CB-839: Calithera Biosciences, Inc

  • ABT-869: AbbVie

  • Nivolumab: Bristol-Myers Squibb

  • ABT-510/Thrombospondin-1 mimetic: Abbott

  • bevacizumab: SCRI Development Innovations, LLC

  • CP-461: Astellas Pharma Inc

 

Discover more about therapies set to grab major Advanced Renal Cell Carcinoma market share @ Advanced Renal Cell Carcinoma Treatment Landscape

 

Advanced Renal Cell Carcinoma Market Strengths

  • The incidence of RCC has increased in recent years leading to more focus by pharmaceutical firms. 

  • Antiangiogenics in association with targeted immunotherapy is overcoming resistance emphasizing the role of the tumor microenvironment (TME) and this strategy is currently an option in first line treatment.

 

Advanced Renal Cell Carcinoma Market Opportunities

  •  There are ongoing trials addressing unanswered questions, such as (CAR) T-cell therapy.

 

Scope of the Advanced Renal Cell Carcinoma Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Advanced Renal Cell Carcinoma Companies: Dana-Farber Cancer Institute, Huabo Biopharm Co., Ltd., Beijing Scitech-Mq Pharmaceuticals, Oxford BioMedica, Hutchison Medipharma Limited, Takeda, Amgen, Novartis, AVEO Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, Pfizer, Calithera Biosciences, Inc, AbbVie, Bristol-Myers Squibb, Abbott, SCRI Development Innovations, LLC, Astellas Pharma Inc, and others

  • Key Advanced Renal Cell Carcinoma Therapies: Bevacizumab, HB0025, ST-1898 tablets, Trovax, fruquintinib+sintilimab, Cabozantinib, AMG 102, Pazopanib, tivozanib (AV-951), Belzutifan, Temsirolimus (CCI-779), CB-839, ABT-869, Nivolumab, ABT-510/Thrombospondin-1 mimetic, bevacizumab, CP-461, and others

  • Advanced Renal Cell Carcinoma Therapeutic Assessment: Advanced Renal Cell Carcinoma current marketed and Advanced Renal Cell Carcinoma emerging therapies

  • Advanced Renal Cell Carcinoma Market Dynamics: Advanced Renal Cell Carcinoma market drivers and Advanced Renal Cell Carcinoma market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Advanced Renal Cell Carcinoma Unmet Needs, KOL’s views, Analyst’s views, Advanced Renal Cell Carcinoma Market Access and Reimbursement 

 

To know more about Advanced Renal Cell Carcinoma companies working in the treatment market, visit @ Advanced Renal Cell Carcinoma Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Advanced Renal Cell Carcinoma Market Report Introduction

2. Executive Summary for Advanced Renal Cell Carcinoma

3. SWOT analysis of Advanced Renal Cell Carcinoma

4. Advanced Renal Cell Carcinoma Patient Share (%) Overview at a Glance

5. Advanced Renal Cell Carcinoma Market Overview at a Glance

6. Advanced Renal Cell Carcinoma Disease Background and Overview

7. Advanced Renal Cell Carcinoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Advanced Renal Cell Carcinoma 

9. Advanced Renal Cell Carcinoma Current Treatment and Medical Practices

10. Advanced Renal Cell Carcinoma Unmet Needs

11. Advanced Renal Cell Carcinoma Emerging Therapies

12. Advanced Renal Cell Carcinoma Market Outlook

13. Country-Wise Advanced Renal Cell Carcinoma Market Analysis (2020–2034)

14. Advanced Renal Cell Carcinoma Market Access and Reimbursement of Therapies

15. Advanced Renal Cell Carcinoma Market Drivers

16. Advanced Renal Cell Carcinoma Market Barriers

17.  Advanced Renal Cell Carcinoma Appendix

18. Advanced Renal Cell Carcinoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Renal Cell Carcinoma Market Report 2034: Epidemiology Data, Therapies, Latest Drug Approvals | DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis, AVEO

Schneider Electric partners with Manhattan Associates in global transformation drive

Schneider Electric has confirmed its partnership with Manhattan Associates. This tie-up heralds Schneider’s intention to boost its worldwide distribution and transportation operations as part of an ambitious business-wide transformation drive.

These efforts involve deploying Manhattan’s Active Supply Chain. This merges Manhattan Active Warehouse Management (WM) and Manhattan Active Transport Management (TM), designed to optimize the company’s strategic overhaul. It is set to be rolled out in over 20 of Schneider’s distribution centres, and there are additional plans to implement Manhattan Active in 200+ other operational sites.

According to Schneider Electric, this unified approach, made possible by Manhattan Active Supply Chain, is expected to maximise inventory efficiency, enhance processes, and promote workforce agility globally.

Stuart Michael Whiting, Senior Vice President of Global Supply Chain (GSC) Logistics and Planning at Schneider Electric, stated: “After 12 successful years with a Manhattan WMS, we decided to update to Manhattan Active Warehouse Management and extend it with Manhattan Active Transportation Management. These two cloud-native solutions represent a significant step forward for our supply chain execution and are another exciting stride forward on our ongoing business-wide transformation journey.”

Fully adopting these cloud-based solutions is a major step in overhauling Schneider’s supply-chain execution and a significant leap in its transformation strategy. This update from a Manhattan Warehouse Management System (WMS) to an Active WMS provides a renewed network in Schneider’s global distribution, impacting its transportation, labour, and automation processes.

Henri Seroux, Senior Vice President of EMEA at Manhattan Associates, added: “Over the last decade, Manhattan had proven itself a valuable and highly capable WMS partner to Schneider Electric. The upgrade to Manhattan’s unified supply chain solution will grant Schneider centralised control over its distribution, transportation, labour, and automation. This process is expected to result in significant efficiency, productivity, and agility gains to the company.”

Manhattan’s unified solution will significantly enhance visibility and control across the entire network of Schneider Electric’s distribution centres and transport operations on a global scale. “Manhattan’s unified supply chain solution will help us optimise inbound and outbound planning and execution, giving us unprecedented levels of visibility and control across our entire global network of distribution centres and transport operations,” Whiting concluded.

About Schneider Electric

Schneider’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On. Our mission is to be your digital partner for Sustainability and Efficiency. We drive digital transformation by integrating world-leading process and energy technologies, end-point to cloud connecting products, controls, software and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure and industries.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric partners with Manhattan Associates in global transformation drive

Schneider Electric Foundation Turns 25 and Launches the ‘25 Years Young’ Campaign

To mark the 25th anniversary of its foundation, Schneider Electric, the leader in the digital transformation of energy management and automation, is launching a global campaign in celebration of both this key milestone and the next generation of young leaders committed to building a fairer, low-carbon society.

‘25 Years Young’: A Celebration of Youth and 25 Years of Action 

Founded in 1999 under the aegis of the Fondation de France, the Schneider Electric Foundation supports changemakers driving sustainable development, promoting social inclusion, and empowering communities worldwide. Throughout 2024, the foundation will celebrate the world’s youth by raising awareness of their social and environmental impact and mobilizing the support of company employees. The high point of these celebrations is the launch of a global call for contributions with the foundation’s social entrepreneurship partner, Ashoka.

Ever since its creation, the Schneider Electric Foundation has been a pioneer in supporting positive initiatives to tackle growing social challenges and many innovations are driven by young people from around the world. The foundation is honoring them on its 25th anniversary by supporting their future, our future, helping them to make an impact for a fairer energy transition.

“Youth Innovation For A Sustainable Future”: A Global Call for Contributions 

The call for contributions titled ‘Youth Innovation For A Sustainable Future’ with Ashoka’s program Changemaker Companies aims to select 25 of the most impactful and innovative youth projects across all five continents (Africa, the Americas, Asia, Europe, and the Middle East). This global call for contributions focuses on professional training, entrepreneurship and a fair transition, and a 50,000-euro prize will be awarded to the winning project during the COP29 climate summit in Bakou, Azerbaïdjan. Those projects selected will also benefit from increased visibility across the social media channels of both Schneider Electric’s Foundation and Ashoka’s network of countries.

Gilles Vermot Desroches, Senior Vice President of Schneider Electric Corporate Citizenship and Institutional Affairs and General delegate of the Schneider Electric Foundation declared:

“The younger generation is playing an influential role in how we shape tomorrow’s innovative solutions. From the outset, the SEF has valued the contribution of youth, and therefore, considers the importance of supporting young people to nurture both future generations and our planet.”

About the Schneider Electric Foundation 

In a world where social and environmental challenges are more widespread and more urgent than ever, the Schneider Electric Foundation supports innovative and forward-looking initiatives to give as many people as possible the energy they need to succeed.

Always forward-looking and optimistic, the goal of the Schneider Electric Foundation is to play a part in creating a fairer, less carbon-intensive society that gives future generations the tools to transform our world.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric Foundation Turns 25 and Launches the ‘25 Years Young’ Campaign

Schneider Electric releases 7-ft and 20-ft BESS designs

Schneider Electric has unveiled an energy storage system for grid-scale applications. The company’s Battery Energy Storage System (BESS) is the cornerstone for a fully integrated microgrid solution driven by Schneider Electric’s controls, optimization, and world-renowned digital and field services.

Distribution company Graybar is the first channel partner for Schneider Electric’s new BESS, offered as part of the EcoStruxure Microgrid Flex system.

“With over two decades of expertise in battery conversion, we are proud to introduce a solution meticulously crafted with flexibility at its core,” said Jana Gerber, Schneider Electric’s President of North America Microgrids. “Our aim is to streamline energy expenditures while amplifying the use of renewable resources, including solar PV. Combining our proven track record of innovation with Graybar’s focus on renewable energy solutions will accelerate this mission.”

Comprised of a lithium-iron phosphate battery system, battery management system, power conversion system and controller, BESS has been tested and validated to work alongside Schneider Electric’s standardized microgrid system, EcoStruxure Microgrid Flex, and fully integrated into the software suite, which includes EcoStruxure Microgrid Operation, and EcoStruxure Microgrid Advisor. With a scalable configuration and advanced safety controls, BESS minimizes energy costs and features:

  • Full Integration: The all-in-one enclosure incorporates pre-integrated components for both AC-coupled and DC-coupled BESS, streamlining site engineering, construction, and installation processes while minimizing labor and material expenses. The paralleling capability enables multiple BESS units to function as a unified entity. This comprehensive integration encompasses inverters, batteries, cooling systems, transformers, safety features, and controls, ensuring optimal performance and efficiency.
  • UL Certified and Compliant: The solution is fully certified and compliant with UL 9540 certification and has a fire safety system design aligned with the latest standards outlined in NFPA 855.
  • Easy Installation & Maintenance: The ready-to-deploy system, featuring a tested, validated, and documented architecture (TVDA), facilitates installation processes, surpassing the efficiency of traditional custom-engineered designs. The solution also integrates with energy management systems (EMS), significantly reducing integration time and minimizing field errors.
  • Resilience: The system offers bidirectional connectivity to the grid, providing the flexibility to operate as either grid-connected or off-grid. With the capacity to store energy for immediate access during outages, BESS can deliver up to 2 MW of power when needed.

There are two connection-ready BESS options available: a small, hybrid 7-ft NEMA 3R Enclosure that is both AC- and DC-coupled and a medium 20-ft NEMA 3R Enclosure that is AC-coupled. Both feature scalable configurations with various options available from 60 kW to 2 MW in 2-hr and 4-hr configurations.

About Schneider Electric

Schneider’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On. Our mission is to be your digital partner for Sustainability and Efficiency. We drive digital transformation by integrating world-leading process and energy technologies, end-point to cloud connecting products, controls, software and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure and industries.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric releases 7-ft and 20-ft BESS designs

Schneider Electric adds BESS to EcoStruxure Microgrid Flex system

Schneider Electric is adding a full Battery Energy Storage System to its integrated microgrid solution, the Schneider Electric BESS, that is driven by Schneider Electric’s controls, optimization, and field services. 

“With over two decades of expertise in battery conversion, we are proud to introduce a solution meticulously crafted to serve multiple energy needs,” said Jana Gerber, Schneider Electric’s President of North America Microgrids. “Our aim is to streamline energy expenditures while amplifying the use of renewable resources, including solar PV.” 

With the capacity to store energy for immediate access during outages, Schneider Electric BESS can deliver up to 2 MW of power when needed. There are two connection-ready BESS options available:

  • a small, hybrid 7-feet NEMA 3R Enclosure that is both AC and DC coupled and
  • a medium 20-feet NEMA 3R Enclosure that is AC coupled.

Sizes for the Schneider Electric BESS family range from 60 kW to 2 MW in 2h and 4h configurations. 

Schneider Electric BESS has been tested and validated to work as an integral component of Schneider Electric’s standardized microgrid system, EcoStruxure Microgrid Flex, and fully integrated into the software suite, which includes EcoStruxure Microgrid Operation, and EcoStruxure Microgrid Advisor. Electrical, communications, and data networking products distributor Graybar is the inaugural channel partner for Schneider Electric’s new BESS, offered as part of the EcoStruxure Microgrid Flex system. Renewable energy is a growing part of Graybar’s comprehensive portfolio of solutions.  

What makes a BESS?

As part of a microgrid system, BESS captures energy from different sources, accumulates this energy, and stores it in rechargeable batteries for later use. Battery Energy Storage is the Distributed Energy Resource that enables most customer energy-use cases, including resiliency, demand-charge reduction, grid services, renewable self-consumption, decarbonization of electrical energy, and variable generation smoothing.  The stored energy from a BESS can be discharged to supply power to office, industrial, and commercial facilities, electric vehicles, or the grid.  

Schneider Electric BESS

The Schneider Electric BESS is comprised of a battery system, battery management system, power conversion system, and controller, as well as advanced safety controls. BESS features include:  

  • All-in-one enclosure with pre-integrated components.
  • The paralleling capability enables multiple BESS units to function as a unified entity. This comprehensive integration encompasses inverters, batteries, cooling systems, transformers, safety features, and controls, ensuring optimal performance and efficiency.  
  • Fully compliance with UL 9540 certification. The Schneider BESS has a cutting-edge fire safety system design aligned with the latest standards outlined in NFPA 855.  
  • Integrates with Schneider Electric’s Energy Management Systems (EMS) to reduce integration time and minimizing field errors.  
  • Bidirectional connectivity to the grid to operate as either grid-connected or off-grid.
  • Peace of Mind: Comprehensive services and support available throughout the lifecycle of the project and warranty execution for optimal maintenance and care.  

“Our new Battery Energy Storage System marks a significant step forward in bringing resilient, sustainable, and economical energy solutions to the market,” Gerber said. “Amidst the global pursuit of net-zero objectives and the imperative for an enhanced grid, BESS strategically harnesses onsite generation capabilities to deliver substantial energy savings while maximizing renewable integration.”

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric adds BESS to EcoStruxure Microgrid Flex system

Premium Quality Asphalt Services by Experienced Contractors in Driveways and Roadways

Premium Quality Asphalt Services by Experienced Contractors in Driveways and Roadways
Asphalt has become a game changer, given its numerous benefits to property owners and road users. The various benefits include an improved driving experience and beautification of the property exterior, making it look stunning. Additionally, it is easy to maintain and serves the owners for a long time.

Smithfield, VA – Smithfield Paving Contractors is an asphalt company providing premium asphalt services to all clients. The company is fully licensed, ensuring quality services to all its clients. The main goal of the driveway paving Smithfield Company is to ensure that their clients maximize their residential and commercial properties and get the best possible experience. 

As previously highlighted in their website post, Smithfield Paving Contractors has several years of experience providing high-quality parking lot paving Smithfield services. The company specializes in tar and chip paving and asphalt paving, which they handle expertly regardless of the size of the project, whether for a residential or commercial property. The company offers premium paving solutions for clients requiring basic or driveway installation. 

In their previous website post, Smithfield Paving Contractors mentioned offering a friendly and reliable service. The commercial asphalt paving Smithfield professionals listen keenly to the different needs of their clients and guide them on the best way to get the job done right. The company is trustworthy and honest, working diligently to meet the needs of its clients. 

Smithfield Paving Contractors provides a wide range of asphalt services, making them the go-to place for all asphalt services. Their skills enable them to deliver a high-quality service that meets their clients’ different needs. Also, the parking lots are designed to meet the unique needs of their clients. 

About Us

Smithfield Paving Contractors is a reliable and professional company with several years of experience. Call today! 

Media Contact
Company Name: Smithfield Paving Contractors
Contact Person: Coleman Reddish
Email: Send Email
Phone: (757) 364-0860
Address:1807 S Church St #2
City: Smithfield
State: VA
Country: United States
Website: http://smithfieldpavingcontractors.com/

Dpei Max Announces Major Technological Upgrades and Product Innovations to Enhance Customer Experience and Efficiency

Dpei Max, a leading force in the financial services industry, is thrilled to announce significant technological upgrades to its platform alongside the launch of new innovative products. These advancements are designed to dramatically improve customer experience and operational efficiency, setting new standards in the financial sector.

The latest technological upgrades include:

  • Advanced Trading Algorithms: Dpei Max has developed sophisticated algorithms that optimize trading strategies, providing clients with faster, more accurate market analysis and execution.

  • Enhanced Data Security: Understanding the importance of data integrity, Dpei Max has implemented state-of-the-art encryption and security protocols to ensure the highest level of data protection for its clients.

  • User Interface Improvements: The Dpei Max platform now boasts a more intuitive and user-friendly interface, making it easier for clients to navigate and manage their investments efficiently.

Alongside these technological upgrades, Dpei Max is excited to introduce several innovative products:

  • Smart Investment Tools: New tools that leverage artificial intelligence to offer personalized investment advice based on individual risk profiles and investment goals.

  • Real-Time Analytics Dashboard: This new feature provides clients with real-time insights into market trends and portfolio performance, enabling quicker and more informed decision-making.

  • Mobile Trading App: A newly designed app that allows clients to execute trades and monitor their portfolios from anywhere in the world, directly from their mobile devices.

“Dpei Max is committed to continually pushing the boundaries of what is possible in financial technology,” said Heric, Head of Technology at Dpei Max. “Our latest technological upgrades and product launches are a testament to our dedication to providing our clients with superior tools and services that enhance their trading experience and success.”

These enhancements are part of Dpei Max’s ongoing strategy to integrate cutting-edge technology into its services, ensuring that it remains at the forefront of the financial services industry. By focusing on technology and innovation, Dpei Max aims to not only meet but exceed client expectations in a rapidly evolving digital world.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: Dpei Max
Contact Person: Peter
Email: Send Email
Country: United Kingdom
Website: https://website.wealthfront.club

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dpei Max Announces Major Technological Upgrades and Product Innovations to Enhance Customer Experience and Efficiency